LONDON — GSK said Tuesday it would purchase Bellus Health for $2 billion, adding a promising chronic cough drug to its pipeline.
The all-cash deal values Bellus, based in Laval, Canada, at $14.75 a share, roughly double Monday’s closing stock price.
With the acquisition, GSK will get the experimental drug camlipixant, which is in a Phase 3 trial for refractory chronic cough. A readout from the study is expected in the second half of 2024, Bellus has said previously. GSK said it anticipates the medicine could receive regulatory approval in 2026.
Create a display name to comment
This name will appear with your comment